In 2003, Cass and colleagues [20] made the surprising observation that a group of ovarian carcinoma patients with BRCA1 and BRCA2 mutations had a significantly higher (72%) response rate to primary platinum-based chemotherapy than patients with sporadic disease (36%). The gene discussed is BRCA2; the disease is ovarian carcinoma.